PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Grants and Contracts Details

StatusActive
Effective start/end date2/27/20 → 10/30/25

Funding

  • Alpha Oncology Incorporated: $191,675.00